24/7 Market News- Harrow Reports Q2 2024 Financial Results
DENVER, Colo., Aug 08, 2024 (247marketnews.com)- Harrow (Nasdaq: HROW) reported its second quarter 2024 results, including record revenues of $48.9 million, adjusted EBITDA of $8.8 million, 98% increase in IHEEZO customer unit demand volume and a 212% increase in VEVYE total prescriptions, from the first quarter of 2024. Harrow also posted its second quarter Letter to Stockholders and corporate presentation on its “Investors” section of its website at harrow.com.
Harrow’s CEO, Mark L. Baum, stated, “The second quarter of 2024 marked a financial and operational turning point for Harrow, with revenues surging 46% compared to the same quarter last year and 42% over the previous quarter.
“This remarkable growth, which was years in the making, was driven by exceptional performance across all Harrow business segments, most notably IHEEZO and VEVYE. Our team also continues to advance the relaunch of TRIESENCE during 2024, with initial analytical test results for the second process performance qualification (PPQ) batch demonstrating in-specification results and the third PPQ batch scheduled to be manufactured in a matter of days. This outstanding quarterly report is a testament to the dedication of the entire Harrow Family, which is being continuously strengthened by the addition of experienced and motivated high-impact individuals. We are excited about where we are today, confident that we are poised for, and expect to achieve, further revenue and profitability expansion in the coming quarters and years.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (HROW)
- Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
- Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
- Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
- Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
- harrow relaunches triesence®